On September 29, Twist Bioscience Corp rose 5.35% in regular trading, trading around $189.2 per share, with turnover of approximately $22.91 million, extending its recent strong upward trajectory.
On the news front, the rally is driven by continued market enthusiasm around the company's positioning as a key infrastructure provider in the AI-powered drug discovery value chain. On September 16, Twist announced a collaboration with Lilly TuneLab, Eli Lilly's AI/ML drug discovery platform, to provide antibody characterization data services supporting AI-based druggability prediction and validation workflows. Earlier in August, the company was selected by Anthropic as an independent evaluator for a multi-arm AI protein design project, a development that triggered a 17% single-day surge at the time.
Twist's proprietary silicon-based DNA synthesis platform positions it as a critical enabler in the emerging AI design-to-wet-lab validation loop, a role frequently described as a pick-and-shovel play in the accelerating AI pharma sector. Separately, UBS initiated coverage on September 9 with a Neutral rating and a $144 price target, while Q3 results in August showed revenue of $118.4 million beating estimates, with Q4 guidance of $123-124 million also above consensus.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments